文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

系统性硬化症的发病机制。

The pathogenesis of systemic sclerosis.

机构信息

Department of Medicine, University of California, San Francisco, 94143, USA.

出版信息

Annu Rev Pathol. 2011;6:509-37. doi: 10.1146/annurev-pathol-011110-130312.


DOI:10.1146/annurev-pathol-011110-130312
PMID:21090968
Abstract

Systemic sclerosis (SSc), also known as scleroderma, is a rare connective tissue disease characterized by vascular and immune dysfunction, leading to fibrosis that can damage multiple organs. Its pathogenesis is complex and poorly understood. Two major clinical subtypes are the limited and diffuse forms. Research into SSc has been hampered by its rarity, its clinical heterogeneity, and the lack of mouse models that accurately recapitulate the disease. Clinical and basic studies have yielded some mechanistic clues regarding pathogenesis. Recent insights gained through the use of microarrays have revealed distinctive subsets of SSc within and beyond the limited and diffuse subsets. In this review, we discuss potential mechanisms underlying the vascular, autoimmune, and fibrotic points of dysregulation. Proper categorization of SSc patients for research studies by use of microarrays or other biomarkers is critical, as disease heterogeneity may explain some of the inconsistencies of prior studies.

摘要

系统性硬化症(SSc),也称为硬皮病,是一种罕见的结缔组织疾病,其特征为血管和免疫功能障碍,导致纤维化,从而损害多个器官。其发病机制复杂,尚不清楚。两种主要的临床亚型为局限性和弥漫性。由于其罕见性、临床异质性以及缺乏准确再现疾病的小鼠模型,SSc 的研究受到阻碍。临床和基础研究已经为发病机制提供了一些机制线索。最近通过使用微阵列获得的新见解揭示了局限性和弥漫性亚型内和之外的 SSc 的独特亚群。在这篇综述中,我们讨论了血管、自身免疫和纤维化失调的潜在机制。通过使用微阵列或其他生物标志物对 SSc 患者进行适当的分类对于研究至关重要,因为疾病异质性可能解释了先前研究的一些不一致性。

相似文献

[1]
The pathogenesis of systemic sclerosis.

Annu Rev Pathol. 2011

[2]
Animal models of scleroderma: lessons from transgenic and knockout mice.

Curr Opin Rheumatol. 2009-11

[3]
Role of IL-13 in systemic sclerosis.

Cytokine. 2011-9-14

[4]
T cell abnormalities in systemic sclerosis with a focus on Th17 cells.

Eur Cytokine Netw. 2012

[5]
Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis.

Arthritis Rheum. 2009-4

[6]
The lung megakaryocytes and pulmonary fibrosis in systemic sclerosis.

Med Hypotheses. 2009-3

[7]
Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis.

J Dermatol Sci. 2005-7

[8]
Systemic sclerosis: a prototypic multisystem fibrotic disorder.

J Clin Invest. 2007-3

[9]
A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis.

Discov Med. 2010-8

[10]
Macro- and microvascular disease in systemic sclerosis.

Vascul Pharmacol. 2015-8

引用本文的文献

[1]
NMR based clinical metabolomics revealed altered lipid and sugar metabolism in systemic sclerosis with implications for diagnosis and therapeutic strategies.

Sci Rep. 2025-8-21

[2]
Identification of serum exosome proteins in systemic sclerosis with interstitial lung disease by aptamer proteomics.

Arthritis Res Ther. 2025-7-10

[3]
Histopathological and molecular analysis in dermis and epidermis of patients with systemic and localized scleroderma.

North Clin Istanb. 2025-4-22

[4]
Immune Memory: A New Frontier in Treating Recurrent Inflammatory Skin Diseases.

Clin Rev Allergy Immunol. 2025-3-18

[5]
and Gene Polymorphisms in Systemic Sclerosis.

Balkan J Med Genet. 2025-3-6

[6]
The complexities of cell death mechanisms: a new perspective in systemic sclerosis therapy.

Apoptosis. 2025-4

[7]
A Scleroderma and Raynaud's UK (SRUK) national survey to explore rheumatologists' awareness, approaches to diagnosis and management and training needs within systemic sclerosis.

Rheumatol Adv Pract. 2024-12-20

[8]
BMP-4 and fetuin A in systemic sclerosis patients with or without calcinosis.

Front Immunol. 2024-12-3

[9]
Salirasib Inhibits the Expression of Genes Involved in Fibrosis in Fibroblasts of Systemic Sclerosis Patients.

Immun Inflamm Dis. 2024-11

[10]
An evaluation of autonomic and gastrointestinal symptoms, and gastric emptying, in patients with systemic sclerosis.

J Scleroderma Relat Disord. 2024-10-24

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索